BiotechTube
Sonoma Biotherapeutics

Sonoma Biotherapeutics

Seattle, United States· Est.
sonomabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $335M

Overview

Sonoma Biotherapeutics is a private, clinical-stage biotech founded in 2019 and headquartered in Seattle, USA. The company is pioneering a novel class of living cell therapies using engineered regulatory T cells (Tregs) to treat autoimmune and inflammatory diseases, building directly on the Nobel Prize-winning science of its co-founders. With a strong syndicate of blue-chip life science investors, SonomaBio has advanced its lead candidate into Phase 1 trials and is validating its proprietary platform. The company aims to shift the treatment paradigm from chronic symptom management to potential cures in a vast and underserved market.

Autoimmune DiseasesInflammatory Diseases

Technology Platform

Proprietary platform for engineering and expanding autologous regulatory T cells (Tregs), including genetic modification for enhanced specificity, persistence, and function to restore immune tolerance.

Funding History

3
Total raised:$335M
Venture$30M
Series B$265M
Series A$40M

Opportunities

The massive, underserved autoimmune disease market represents a multi-billion dollar opportunity for a curative therapy.
Successful clinical validation of the Treg platform in one indication would de-risk and enable rapid expansion into numerous other autoimmune and inflammatory conditions, creating a broad pipeline.
The company's strong scientific foundation and Nobel-recognized technology make it an attractive partner for large pharmaceutical companies seeking next-generation immunology assets.

Risk Factors

As a pioneer in engineered Treg therapy, the company faces unproven long-term safety and durability risks for its novel modality.
The complex, autologous manufacturing process presents significant scalability and cost challenges.
The competitive landscape includes other cell therapy approaches and improving conventional biologics, which could impact commercial adoption and reimbursement for a likely high-cost, one-time treatment.

Competitive Landscape

SonomaBio operates in the emerging field of regulatory T cell therapy, competing with other biotechs like GentiBio, Kyverna Therapeutics (focused on CAR-Tregs), and Sangamo Therapeutics, as well as academic consortia. It also competes indirectly with all developers of immunosuppressive biologics and small molecules for autoimmune diseases. Its key competitive advantages are its foundational science from Nobel laureate co-founders and its early clinical validation in rheumatoid arthritis.

More companies in Cell & Gene Therapy →More companies in United States →